Patent: 9,365,632
✉ Email this page to a colleague
Summary for Patent: 9,365,632
Title: | Exendin-4 derivatives as dual GLP1/glucagon agonists |
Abstract: | The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake. |
Inventor(s): | Haack; Torsten (Frankfurt am Main, DE), Wagner; Michael (Frankfurt am Main, DE), Henkel; Bernd (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE), Evers; Andreas (Frankfurt am Main, DE), Bossart; Martin (Frankfurt am Main, DE) |
Assignee: | SANOFI (Paris, FR) |
Application Number: | 14/049,597 |
Patent Claims: | see list of patent claims |
Details for Patent 9,365,632
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/20/2000 | ⤷ Try a Trial | 2032-10-09 |
Sanofi-aventis U.s. Llc | LANTUS | insulin glargine | Injection | 021081 | 04/25/2007 | ⤷ Try a Trial | 2032-10-09 |
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | 06/16/2005 | ⤷ Try a Trial | 2032-10-09 |
Novo Nordisk Inc. | LEVEMIR | insulin detemir | Injection | 021536 | 10/31/2013 | ⤷ Try a Trial | 2032-10-09 |
Amryt Pharmaceuticals Dac | MYALEPT | metreleptin | For Injection | 125390 | 02/24/2014 | ⤷ Try a Trial | 2032-10-09 |
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2032-10-09 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/18/2014 | ⤷ Try a Trial | 2032-10-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |